BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Silva-Abreu M, Calpena AC, Andrés-Benito P, Aso E, Romero IA, Roig-Carles D, Gromnicova R, Espina M, Ferrer I, García ML, Male D. PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. Int J Nanomedicine 2018;13:5577-90. [PMID: 30271148 DOI: 10.2147/IJN.S171490] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Anand B, Wu Q, Nakhaei-nejad M, Karthivashan G, Dorosh L, Amidian S, Dahal A, Li X, Stepanova M, Wille H, Giuliani F, Kar S. Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology. Bioactive Materials 2022;17:506-25. [DOI: 10.1016/j.bioactmat.2022.05.030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wu Q, Karthivashan G, Nakhaei-Nejad M, Anand BG, Giuliani F, Kar S. Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology. Int J Biol Macromol 2022:S0141-8130(22)01851-7. [PMID: 36030976 DOI: 10.1016/j.ijbiomac.2022.08.148] [Reference Citation Analysis]
3 Huang X, Zhang Y, Zhang W, Qin C, Zhu Y, Fang Y, Wang Y, Tang C, Cao F. Osteopontin-Targeted and PPARδ-Agonist-Loaded Nanoparticles Efficiently Reduce Atherosclerosis in Apolipoprotein E-/- Mice. ACS Omega 2022;7:28767-78. [PMID: 36033674 DOI: 10.1021/acsomega.2c00575] [Reference Citation Analysis]
4 Wang P, Wang Y, Li P, Chen C, Ma S, Zhao L, He H, Yin T, Zhang Y, Tang X, Gou J. Oral delivery of polyester nanoparticles for brain-targeting: Challenges and opportunities. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.07.034] [Reference Citation Analysis]
5 Pinto M, Silva V, Barreiro S, Silva R, Remião F, Borges F, Fernandes C. Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform. Ageing Res Rev 2022;79:101658. [PMID: 35660114 DOI: 10.1016/j.arr.2022.101658] [Reference Citation Analysis]
6 Poudel P, Park S. Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics 2022;14:835. [DOI: 10.3390/pharmaceutics14040835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hinge NS, Kathuria H, Pandey MM. Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's. Applied Materials Today 2022;26:101303. [DOI: 10.1016/j.apmt.2021.101303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Todaro B, Moscardini A, Luin S. Pioglitazone-Loaded PLGA Nanoparticles: Towards the Most Reliable Synthesis Method. Int J Mol Sci 2022;23:2522. [PMID: 35269665 DOI: 10.3390/ijms23052522] [Reference Citation Analysis]
9 Annu, Sartaj A, Qamar Z, Md S, Alhakamy NA, Baboota S, Ali J. An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurological Disorders and Brain Tumor. Front Bioeng Biotechnol 2022;10:788128. [DOI: 10.3389/fbioe.2022.788128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Male D, Gromnicova R. Nanocarriers for Delivery of Oligonucleotides to the CNS. Int J Mol Sci 2022;23:760. [PMID: 35054957 DOI: 10.3390/ijms23020760] [Reference Citation Analysis]
11 Goel H, Kalra V, Verma SK, Dubey SK, Tiwary AK. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. J Control Release 2021;341:782-811. [PMID: 34906605 DOI: 10.1016/j.jconrel.2021.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Revdekar A, Shende P. Block copolymers in Alzheimer's disease therapy: A perceptive to revolutionize biomaterials. J Control Release 2021;340:271-81. [PMID: 34763003 DOI: 10.1016/j.jconrel.2021.11.007] [Reference Citation Analysis]
13 Silva-Abreu M, Miralles E, Kamma-Lorger CS, Espina M, García ML, Calpena AC. Stabilization by Nano Spray Dryer of Pioglitazone Polymeric Nanosystems: Development, In Vivo, Ex Vivo and Synchrotron Analysis. Pharmaceutics 2021;13:1751. [PMID: 34834165 DOI: 10.3390/pharmaceutics13111751] [Reference Citation Analysis]
14 Ege D. Action Mechanisms of Curcumin in Alzheimer's Disease and Its Brain Targeted Delivery. Materials (Basel) 2021;14:3332. [PMID: 34208692 DOI: 10.3390/ma14123332] [Reference Citation Analysis]
15 Miralles-Cardiel E, Silva-Abreu M, Calpena AC, Casals I. Development and Validation of an HPLC-MS/MS Method for Pioglitazone from Nanocarriers Quantitation in Ex Vivo and In Vivo Ocular Tissues. Pharmaceutics 2021;13:650. [PMID: 34063615 DOI: 10.3390/pharmaceutics13050650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhi K, Raji B, Nookala AR, Khan MM, Nguyen XH, Sakshi S, Pourmotabbed T, Yallapu MM, Kochat H, Tadrous E, Pernell S, Kumar S. PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP. Pharmaceutics 2021;13:500. [PMID: 33917577 DOI: 10.3390/pharmaceutics13040500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Abbas M. Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer's Patients. Polymers (Basel) 2021;13:1051. [PMID: 33801619 DOI: 10.3390/polym13071051] [Reference Citation Analysis]
18 Ribarič S. Nanotechnology Therapy for Alzheimer's Disease Memory Impairment Attenuation. Int J Mol Sci 2021;22:1102. [PMID: 33499311 DOI: 10.3390/ijms22031102] [Reference Citation Analysis]
19 Andrés-Benito P, Gelpi E, Jové M, Mota-Martorell N, Obis È, Portero-Otin M, Povedano M, Pujol A, Pamplona R, Ferrer I. Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. Neuropathol Appl Neurobiol 2021;47:544-63. [PMID: 33332650 DOI: 10.1111/nan.12681] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Binda A, Murano C, Rivolta I. Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer's Disease: A State-of-the-Art (2017-2020). Int J Nanomedicine 2020;15:6113-35. [PMID: 32884267 DOI: 10.2147/IJN.S231480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
21 Wang Y, Wu Q, Anand BG, Karthivashan G, Phukan G, Yang J, Thinakaran G, Westaway D, Kar S. Significance of cytosolic cathepsin D in Alzheimer's disease pathology: Protective cellular effects of PLGA nanoparticles against β-amyloid-toxicity. Neuropathol Appl Neurobiol 2020;46:686-706. [PMID: 32716575 DOI: 10.1111/nan.12647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Quan Q, Li X, Feng J, Hou J, Li M, Zhang B. Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease. Mol Med Rep 2020;22:3277-88. [PMID: 32945455 DOI: 10.3892/mmr.2020.11424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Maghsoudi S, Taghavi Shahraki B, Rabiee N, Fatahi Y, Dinarvand R, Tavakolizadeh M, Ahmadi S, Rabiee M, Bagherzadeh M, Pourjavadi A, Farhadnejad H, Tahriri M, Webster TJ, Tayebi L. Burgeoning Polymer Nano Blends for Improved Controlled Drug Release: A Review. Int J Nanomedicine 2020;15:4363-92. [PMID: 32606683 DOI: 10.2147/IJN.S252237] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
24 Cano A, Ettcheto M, Chang JH, Barroso E, Espina M, Kühne BA, Barenys M, Auladell C, Folch J, Souto EB, Camins A, Turowski P, García ML. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. J Control Release 2019;301:62-75. [PMID: 30876953 DOI: 10.1016/j.jconrel.2019.03.010] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 25.0] [Reference Citation Analysis]
25 Espinoza LC, Silva-Abreu M, Clares B, Rodríguez-Lagunas MJ, Halbaut L, Cañas MA, Calpena AC. Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil. Pharmaceutics 2019;11:E64. [PMID: 30717264 DOI: 10.3390/pharmaceutics11020064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
26 Rincón M, Calpena AC, Fabrega MJ, Garduño-Ramírez ML, Espina M, Rodríguez-Lagunas MJ, García ML, Abrego G. Development of Pranoprofen Loaded Nanostructured Lipid Carriers to Improve Its Release and Therapeutic Efficacy in Skin Inflammatory Disorders. Nanomaterials (Basel) 2018;8:E1022. [PMID: 30544628 DOI: 10.3390/nano8121022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]